Hip to heparin – A Manitoba model for clinical trials

Posted on

A University of Manitoba research team is emerging as a global leader in COVID-19 anticoagulation trials thanks to their innovative, global trial studying different types of heparin, an anticoagulant (blood thinning) and anti-inflammatory drug. Early results released in January show full doses improved outcomes.

The ATTAC trial (antithrombotic therapy to ameliorate complications of COVID-19), is an international multi-platform randomized control trial (mpRCT) led by Ryan Zarychanski, a hematol­ogist, critical care physician and associate professor. He has partnered with Patrick Lawler, at the Peter Munk Cardiac Centre and Ewan Goligher, from the University Health Network, both assistant professors at the University of Toronto….

https://news.umanitoba.ca/hip-to-heparin/

Read More Impact Stories

Posted on
McGill-developed device offers 100 per cent accuracy in as little as 10 minutes, and can be configured to detect a [...]
Posted on
This content is available in French only.
Posted on
The University of Toronto and Moderna, Inc. known for its mRNA-based COVID-19 vaccine plan to work together to develop new [...]